Benzinga | Nov 18, 2021 05:18AM EST

JP Morgan Upgrades Evolent Health to Overweight, Raises Price Target to $37

JP Morgan analyst Anne Samuel upgrades Evolent Health (NYSE:EVH) from Neutral to Overweight and raises the price target from $26 to $37.